Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Dystrophia myotonica WD repeat-containing protein (DMWD) is a WD repeat protein encoded by the DMWD gene on human chromosome 19[11][13][14]. It functions as a regulator and cofactor in the deubiquitinating USP12/DMWD/WDR48 complex, promoting USP12 enzymatic activity[8][9][6][13]. WD repeat proteins generally act as scaffolds for multiprotein complexes, and DMWD is predominantly localized to the cytoplasm and nucleus[9][13]. The gene is located near the DMPK gene, and expanded CTG repeats in DMPK (which cause myotonic dystrophy type 1) can lead to partial silencing of neighboring genes, such as DMWD, through chromatin structural alterations[3][5][12]. DMWD is expressed developmentally and is notably abundant in synapse-dense brain regions[5]. There are currently no known approved drugs that specifically interact with DMWD, and it is not considered a direct therapeutic target at this time[9][13][11].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Dystrophia myotonica WD repeat-containing protein (DMWD).